<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03474289</url>
  </required_header>
  <id_info>
    <org_study_id>SHR-1316-I-101</org_study_id>
    <nct_id>NCT03474289</nct_id>
  </id_info>
  <brief_title>Safety and Tolerability of SHR-1316 in Subjects With Advanced Tumors</brief_title>
  <official_title>A Phase 1 Study to Evaluate the Safety and Tolerability of SHR-1316 in Subjects With Advanced Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu HengRui Medicine Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to access the safety and tolerability of the study drug known as
      SHR-1316 in metastatic/advanced malignancies
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-label, non-randomized, dose escalation/expansion phase I study, SHR-1316 is a
      humanized IgG4 monoclonal antibody that binds specifically to human PD-L1.The major aims of
      the study are to define the safety profile of this new drug, and to determine a recommended
      dose and schedule for potential additional trials.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2018</start_date>
  <completion_date type="Anticipated">October 31, 2019</completion_date>
  <primary_completion_date type="Anticipated">January 30, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>at the end of cycle one(each cycle is 21 days)</time_frame>
    <description>incidence and severity of treatment-related adverse events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose-limiting toxicities (DLTs)</measure>
    <time_frame>at the end of cycle one(each cycle is 21 days)</time_frame>
    <description>Number of participants with DLTs</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">134</enrollment>
  <condition>Tumor</condition>
  <arm_group>
    <arm_group_label>Escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SHR-1316 administrated intravenously(IV) at protocol defined dose levels</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Expansion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SHR-1316 administrated IV in advanced solid tumors and selected tumor type</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SHR-1316</intervention_name>
    <description>Monotherapy</description>
    <arm_group_label>Escalation</arm_group_label>
    <arm_group_label>Expansion</arm_group_label>
    <other_name>HTI-1088</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female ≥18 years of age

          2. Subjects with confirmed advanced malignancies (histologically or cytologically)

          3. ECOG Performance status of 0 or 1

          4. Adequate organ functions

          5. Life expectancy ≥12 weeks;

        Exclusion Criteria:

          1. Subjects with active autoimmune disease.

          2. Systemic cytotoxic chemotherapy, biological therapy, or major surgery within 4 weeks
             of the first dose of trial treatment

          3. Previous received PD-1 or PD-L1 therapy

          4. Known Active central nervous system (CNS) metastases

          5. Known Clinically significant cardiovascular condition

          6. Active infection or an unexplained fever &gt;38.5°C

          7. History of immunodeficiency
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xichun Hu</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fudan University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gang Chen, PhD</last_name>
    <phone>+86 (021)50118422</phone>
    <email>chen_gang@shhrp.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ying Tian</last_name>
    <email>tianying@shhrp.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Fudan University Shanghai Cancer Center</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xichun Hu</last_name>
      <email>xchu2009@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 11, 2018</study_first_submitted>
  <study_first_submitted_qc>March 15, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 22, 2018</study_first_posted>
  <last_update_submitted>March 15, 2018</last_update_submitted>
  <last_update_submitted_qc>March 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 22, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

